Author

B. L. Menasche

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

C. B. Wilen· 3 shared A. Iwasaki· 2 shared B. Israelow· 2 shared J. Wei· 2 shared M. M. Alfajaro· 2 shared T. Mao· 2 shared A. M. Pyle· 1 shared A. Muller· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

C. B. Wilen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53

J. D. Lee, B. L. Menasche, M. Mavrikaki, M. M. Uyemura, S. M. Hong, N. Kozlova, J. Wei, M. M. Alfajaro, R. Filler, A. Muller, T. Saxena, R. R. Posey, P. Cheung, T. Muranen, J. Heng, , F. J. Slack

This study shows that SARS-CoV-2 variants differ in syncytia formation, which affects host chromatin accessibility, cellular senescence, and inflammation via TP53.

bioRxiv · Aug 31, 2023Microbiology

A stem-loop RNA RIG-I agonist confers prophylactic and therapeutic protection against acute and chronic SARS-CoV-2 infection in mice

T. Mao, B. Israelow, C. Lucas, C. B. F. Vogels, O. Fedorova, M. I. Breban, B. L. Menasche, H. Dong, M. Linehan, Yale SARS-CoV-2 Genome Surveillance Initiative, C. B. Wilen, M. L. Landry, N. D. Grubaugh, A. M. Pyle, A. Iwasaki

This study shows that SLR14, a RIG-I agonist, prevents and treats SARS-CoV-2 infection in mice, including chronic cases and variants, through IFN-I responses.

bioRxiv · Jun 16, 2021Immunology

High-affinity, neutralizing antibodies to SARS-CoV-2 can be made in the absence of T follicular helper cells

J. S. Chen, R. D. Chow, E. Song, T. Mao, B. Israelow, K. Kamath, J. Bozekowski, W. A. Haynes, R. B. Filler, B. L. Menasche, J. Wei, M. M. Alfajaro, W. Song, L. Peng, L. Carter, , S. C. Eisenbarth

The paper shows that high-affinity, neutralizing antibodies against SARS-CoV-2 can be produced without T follicular helper cells through alternative pathways.

bioRxiv · Jun 10, 2021Immunology